MiMedx Director Acquires 28,609 Shares in Annual Stock Grant

MiMedx Group Director M. Kathleen Behrens received an annual restricted stock grant of 28,609 shares at $6.47 per share on June 18, 2025, increasing her total direct holdings to 212,771 shares.

Rhea-AI Filing Summary

MiMedx Group Director M. Kathleen Behrens received an annual restricted stock grant of 28,609 shares at $6.47 per share on June 18, 2025, increasing her total direct holdings to 212,771 shares.

Key details of the transaction:

• The grant is part of non-employee director compensation
• Transaction is exempt under Rule 16b-3
• Shares will vest at the earlier of 12 months or the next annual shareholder meeting
• Form 4 was filed by William F. Hulse as attorney-in-fact

This routine compensation grant demonstrates continued alignment between director and shareholder interests through equity-based compensation. The transaction represents approximately 13.4% increase in the director's direct holdings in the company.

Insider Trade Summary

Grant/Award: 28,609 shares

Grant/Award 1 txn

Insider BEHRENS M KATHLEEN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	28,609	$6.47	$185K

Holdings After Transaction: Common Stock — 212,771 shares (Direct)

Footnotes (1)

1. F1. Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MDXG shares did Director M. Kathleen Behrens acquire on June 18, 2025?

Director M. Kathleen Behrens acquired 28,609 shares of MDXG common stock on June 18, 2025, as part of an annual restricted stock grant to non-employee directors at a price of $6.47 per share.

What is the vesting period for MDXG's director stock grants in 2025?

According to the Form 4 filing, the restricted stock grant vests upon the earlier of 12 months or the next annual meeting of shareholders.

How many MDXG shares does M. Kathleen Behrens own after the June 2025 stock grant?

Following the reported transaction, M. Kathleen Behrens directly owns 212,771 shares of MDXG common stock.

Was MDXG's June 2025 director stock grant exempt from Section 16 rules?

Yes, the Form 4 filing specifically notes that the annual restricted stock grant to non-employee directors is exempt under Rule 16b-3.

What is M. Kathleen Behrens' role at MDXG according to the Form 4?

According to the Form 4 filing, M. Kathleen Behrens serves as a Director of MDXG (MiMedx Group, Inc.), and is classified as a non-employee director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2025 - 06:42 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BEHRENS M KATHLEEN

(Last) (First) (Middle)

1775 WEST OAK COMMONS COURT

(Street)

MARIETTA GA 30062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MIMEDX GROUP, INC. [ MDXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A		28,609(1)	A	$6.47	212,771	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders

Remarks:

	/s/ William F. Hulse as attorney-in-fact M. Kathleen Behrens Wilsey	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.